IPSC News and Press, Century Therapeutics Inc. From 11/04/21

PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that preclinical data from the Company’s CNTY-101 pr...

Collaboration enables Century to explore Outpace’s protein solutions for cell therapy to enhance functionality of iPSC platform Initial program to focus on hematological malignancies with option to expand to additional candidates PHILADELPHIA, Oct. 07, 2021 (GLOBE N...

Century Therapeutics (NASDAQ:IPSC) added to the small-cap Russell 2000 Index as a part of the 3Q21 Russell Indexes IPO additions, effective at US market open on September 20, 2021. “Century’s inclusion in the Russell 2000 Index is an important milestone that reflects o...

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that it will be added to the small-cap Russell 2000® ...

Gainers: Helbiz HLBZ +135%. Corvus Pharmaceuticals CRVS +77%. Innate Pharma IPHA +37%. Worksport (OTCQB:WKSP) +20%. Priority Technology Holdings (NASDAQ:PRTH) +15%. Entasis Therapeutics (NASDAQ:ETTX) +15%. Capital Senior Living Corporation (NYSE:CSU) +13%. Evelo (NASDAQ:EVLO) +...

Point Roberts, WA and Delta, BC - August 27, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, cannabis, mining, cleantech and psychedelics. Today's stocks have been added...

In Q42021 (likely at SITC), AGEN is anticipated to publish updated 1181/Bal Phase 2 clinical data in MSS-CRC that shows 1181/Bal significantly outperforms current FDA approved 3rd line standard-of-care. The broader clinical/investment community may see much faster patient enrollment t...

Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221M June 30, 2021 cash, cash equivalents, and marketable securities of ...

adrian825/iStock via Getty Images Psychedelic drug developers started as buys Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald have initiated Atai Life Sciences ([[ATAI]] +2.3%) with  buy/overweight ratings. Credit Suisse has a $25 price target on shares (~35% upside) Credit...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead It's that time again, as second-quarter earnings season kicks off in earnest with the usual early reports from banks - J...